LONDON, UK: AstraZeneca (NYSE: AZN) today announced a collaboration and investment agreement with Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, to accelerate the development of next-generation therapeutics in areas of high unmet need, including oncology, immunology, and rare diseases. Under the terms of the agreement, AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing…